Projet de hadrontherapie a Lyon - Lignes de faisceau

Ce rapport decrit les lignes de faisceau du projet de hadrontherapie Rhone-Alpes, depuis la region d'extraction dans le synchrotron jusqu'aux chambres d'irradiation

The GUINEVERE Project for Accelerator Driven System Physics

paper 9414International audienceThe GUINEVERE project is part of the EUROTRANS Integrated Project of the 6th EURATOM Framework Programme. It is mainly devoted to ADS on-line reactivity monitoring validation, sub-criticality determination and operational procedures (loading, start-up, shut-down, ...) as a follow-up of the MUSE experiments. The project consists in coupling a fast lead core, set-up in the VENUS reactor at SCK*CEN Mol (B), with a GENEPI neutron source under construction by CNRS. To accommodate the accelerator in a vertical coupling configuration, the VENUS building is being heightened. The fast core will be loaded with enriched Uranium and will be moderated and reflected with solid lead (zero power experiment). For the purpose of the experimental programme, the neutron source has to be operated not only in pulsed mode but also in continuous mode to investigate the current-to-flux reactivity indicator in representative conditions of a powerful ADS. In this latter mode it is also required to make short beam interruptions to have access to the neutron population decrease as a function of time: from this spectrum it will be possible to apply different analysis techniques such as "prompt decay" fitting techniques and "source jerk" techniques. Beam interruptions will be repeated at a programmable frequency to improve time spectra statistics. Different sub-criticality levels (keff=0.99, 0.97, 0.95, ...) will be investigated in order to obtain a full set of data points for the final overall validation of the methodology. This paper describes the status of the experimental facility assembling, and the foreseen experimental programme to be started

The GUINEVERE project at the VENUS facility

Proc. on CD Rom log315International audienceThe GUINEVERE project is an international project in the framework of IP-EUROTRANS, the FP6 program which aims at addressing the main issues for ADS development in the framework of partitioning and transmutation for nuclear waste volume and radiotoxicity reduction. The GUINEVERE project is carried out in the context of domain 2 of IP-EUROTRANS, ECATS, devoted to specific experiments for the coupling of an accelerator, a target and a subcritical core. These experiments should provide an answer to the questions of online reactivity monitoring, sub-criticality determination and operational procedures (loading, start-up, shutdown, …) in an ADS by 2009-2010. The project has the objective to couple a fast lead core, within the VENUS building operated by the SCK•CEN, with a neutron generator able to work in three different modes: pulsed, continuous and continuous with beam interruptions at the millisecond scale. In order to achieve this goal, the VENUS facility has to be adapted and a modified GENEPI-3C accelerator has to be designed and constructed. The paper describes the main modifications to the reactor core and facility and to the accelerator, which will be executed during the years 2008 and 2009, and the experimental programme which will start in 2009

Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model

Background Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. Objective To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air(R) app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods We assessed the MASK-air(R) data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales-VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season. Results We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = -12.1;-2.8), lower VAS Work (average difference = 5.0; 95%CrI = -8.5;-1.5), and a lower CSMS (average difference = 3.7; 95%CrI = -9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = -17.2;-2.8), lower VAS Work (average difference = 7.8; 95%CrI = -15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = -18.5;0.2). Conclusion In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its 'real-world' effectiveness

The Acceleration and Storage of Radioactive Ions for a Beta-Beam Facility

The term beta-beam has been coined for the production of a pure beam of electron neutrinos or their antiparticles through the decay of radioactive ions circulating in a storage ring. This concept requires radioactive ions to be accelerated to as high Lorentz gamma as 150. The neutrino source itself consists of a storage ring for this energy range, with long straight sections in line with the experiment(s). Such a decay ring does not exist at CERN today, nor does a high-intensity proton source for the production of the radioactive ions. Nevertheless, the existing CERN accelerator infrastructure could be used as this would still represent an important saving for a beta-beam facility.Comment: beta-beam working group website at http://cern.ch/beta-bea

Digital Health Europe (DHE) Twinning on Severe Asthma—Kick-off Meeting Report

info:eu-repo/semantics/publishedVersio